

IN RE: REGLAN LITIGATION

SUPERIOR COURT OF NEW JERSEY
LAW DIVISION: MIDDLESEX COUNTY

CASE NO.: 289
Civil Action

MASTER DOCKET: MID-L-10165-14

CASE MANAGEMENT ORDER NO. 29

THIS MATTER having been brought before the Court at a case management conference on January 18, 2018, and counsel for plaintiffs and counsel for defendants having been present and for good cause shown,

IT IS on this 14th day of February, 2018,

ACKNOWLEDGED THAT Case Management Order No. 28 recognized that plaintiffs' counsel in the cases where release deficiencies remained regarding plaintiffs who have agreed to participate in one or more of the settlement programs for the CMO 26 Defendants had agreed to use their best efforts to provide corrected releases or otherwise cure the deficiencies within sixty (60) days of October 17, 2017. Furthermore, it was acknowledged that CMO 26 Defendants had advised plaintiffs' counsel of their reservation of right to seek relief from the Court if, after such sixty (60) day period, the release deficiencies had not been resolved. Notwithstanding the passage of some ninety days, as of the January 18, 2018 conference, fifteen plaintiffs listed on Exhibit A of this CMO have release deficiencies outstanding as to one or more of the CMO 26 defendants; and, accordingly,

IT IS ORDERED THAT in all cases listed on Exhibit A where issues regarding releases remain unresolved for CMO 26 Defendants, counsel for plaintiffs are hereby directed to appear in-person before this Court at the next case management conference on February 27, 2018 at 11:00 a.m., at which time counsel and the Court will resolve any such remaining release deficiencies; and it is also

ACKNOWLEDGED THAT Case Management Order No. 28 required Plaintiffs' Liaison Counsel to identify all cases in which a *Friendly* hearing is required to approve

settlement by October 20, 2017. Plaintiffs' counsel has identified the following five plaintiffs: Meranda Pletzer, Savannah Denault, Justin Newsom, Blake Spoon, and Devon (Hill) Mowell. Now that the remaining defendants have funded their settlements, there are no further impediments to scheduling the *Friendly* hearings. Defendants express concern that fewer than all of the minor plaintiffs requiring a *Friendly* hearing have been identified by Plaintiffs' counsel; and, accordingly,

IT IS ALSO ORDERED THAT counsel for plaintiffs are directed to identify all cases in which a *Friendly* hearing is required to approve settlement, prior to the next case management conference on February 27, 2018 at 11:00 a.m., and to appear in-person or by telephone at the next case management conference, at which time the Court intends to schedule dates for the *Friendly* hearings; and

IT IS FURTHER ORDERED THAT each Plaintiff identified in the attached Exhibit B, who are the plaintiffs who have elected to opt out and not participate in the Teva/PLIVA settlement and, instead to pursue claims against one or more of the defendants PLIVA, Inc., Individually and F/K/A Sidmak Laboratories, Inc.; Barr Pharmaceuticals, LLC F/K/A Barr Pharmaceuticals, Inc.; Barr Laboratories, Inc.; Teva Pharmaceuticals USA, Inc.; and Watson Laboratories, Inc., shall within thirty (30) days of the entry of this Order serve (i) an updated Plaintiff Fact Sheet, newly dated and signed by Plaintiff, or a certification signed by Plaintiff's counsel stating that there are no changes from the Plaintiff Fact Sheet and any amendments thereof, previously served by such Plaintiff; and (ii) accompanying NEW authorizations for all healthcare providers identified in both the original Plaintiff Fact Sheet and any amendments thereto and the Updated Plaintiff Fact Sheet, after which the Court will set case scheduling orders and the parties may thereafter commence case specific discovery.

IT IS FURTHER ORDERED THAT the next case management conference is scheduled for February 27, 2018 at 11:00 a.m.

SO ORDERED:



HONORABLE James F. Hy and J.S.C.

EXHIBIT A

Exhibit A – Remaining Release Deficiencies for CMO 26 Defendants

Claimant Name	Plaintiff Firm	Defendant(s)
Bay, Roxanne	Napoli Shkolnik PLLC	Schwarz; Wyeth
Guillame, Mecca	Marc J. Bern & Partners, LLP	Wyeth
Steele, Eva	Marc J. Bern & Partners, LLP	Schwarz; Wyeth; Alaven
Wilkins, Hilda	Marc J. Bern & Partners, LLP	Mutual
Young, Gail	Oshman & Mirisola, LLP	Wyeth
Charles, Robert	Oshman & Mirisola	Wyeth
Lynn, Craig	Oshman & Mirisola	Wyeth
Shumway, Charles	Oshman & Mirisola	Schwarz; Wyeth; Actavis
Emmett, Dale	Oshman & Mirisola	Wyeth; Alaven
Johnson, Margie	Parker Waichman	Wyeth
Brown, Nannie	Arias Sanguinetti Stahle Torrijos	Wyeth
Sizemore, Mildred	Arias Sanguinetti Stahle Torrijos	Wyeth; Alaven
Alvinakis, Ambria	Arias Sanguinetti Stahle Torrijos	Wyeth
Wendt, Thelma	Tracey & Fox	Alaven
Reeves, Paul	Tracey & Fox	Alaven

EXHIBIT B

Exhibit B – List of Opt-out Cases as to the Teva/PLIVA Settlement

Plaintiff Name	Firm	Docket No.
Benton, Donald	Medical Legal Consultants of Washington	MID-L-010173-14
Downer, Basil	Oshman & Mirisola, LLP	MID-L-010379-14
Eidson, Gloria	Medical Legal Consultants of Washington	MID-L-010248-14
Goodson, Marie	Medical Legal Consultants of Washington	MID-L-010337-14
Holbrook, Cecil	Medical Legal Consultants of Washington	MID-L-010272-14
Jennings, Ruth	Oshman & Mirisola, LLP	MID-L-010041-14
Martinez, Lazaro	Medical Legal Consultants of Washington	MID-L-010482-14
McIntosh, Judy	Oshman & Mirisola, LLP	MID-L-010172-14
Price, Jay	Oshman & Mirisola, LLP	MID-L-010052-14
Schwartz, Michelle	Oshman & Mirisola, LLP	MID-L-010457-14
Villa, Melanie	Oshman & Mirisola, LLP	MID-L-010053-14
Young, Gail	Oshman & Mirisola, LLP	MID-L-010421-14